Systemic sclerosis (ssc) is characterised by extensive tissue fibrosis. Using drugs that are
capable of inhibiting fibroblast activity may be beneficial if administrered early in the
disease course. Thirty adult patients with early SSc will be treated with the endothelin-1
antagonist bosentan for 6 months.Disease progression will be assessed.